• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝脏疾病中的肠道微生物群与宿主反应

Gut Microbiota and Host Reaction in Liver Diseases.

作者信息

Fukui Hiroshi

机构信息

Department of Gastroenterology, Endocrinology and Metabolism, Nara Medical University, 840 Shijo-cho Kashihara, 634-8522 Nara, Japan.

出版信息

Microorganisms. 2015 Oct 28;3(4):759-91. doi: 10.3390/microorganisms3040759.

DOI:10.3390/microorganisms3040759
PMID:27682116
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5023261/
Abstract

Although alcohol feeding produces evident intestinal microbial changes in animals, only some alcoholics show evident intestinal dysbiosis, a decrease in Bacteroidetes and an increase in Proteobacteria. Gut dysbiosis is related to intestinal hyperpermeability and endotoxemia in alcoholic patients. Alcoholics further exhibit reduced numbers of the beneficial Lactobacillus and Bifidobacterium. Large amounts of endotoxins translocated from the gut strongly activate Toll-like receptor 4 in the liver and play an important role in the progression of alcoholic liver disease (ALD), especially in severe alcoholic liver injury. Gut microbiota and bacterial endotoxins are further involved in some of the mechanisms of nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH). There is experimental evidence that a high-fat diet causes characteristic dysbiosis of NAFLD, with a decrease in Bacteroidetes and increases in Firmicutes and Proteobacteria, and gut dysbiosis itself can induce hepatic steatosis and metabolic syndrome. Clinical data support the above dysbiosis, but the details are variable. Intestinal dysbiosis and endotoxemia greatly affect the cirrhotics in relation to major complications and prognosis. Metagenomic approaches to dysbiosis may be promising for the analysis of deranged host metabolism in NASH and cirrhosis. Management of dysbiosis may become a cornerstone for the future treatment of liver diseases.

摘要

尽管给动物喂食酒精会使其肠道微生物发生明显变化,但只有部分酗酒者会出现明显的肠道生态失调,即拟杆菌门减少,变形菌门增加。肠道生态失调与酒精性肝病患者的肠道通透性增加和内毒素血症有关。酗酒者体内有益的乳酸杆菌和双歧杆菌数量也会进一步减少。大量从肠道转移的内毒素会强烈激活肝脏中的Toll样受体4,并在酒精性肝病(ALD)的进展中起重要作用,尤其是在严重酒精性肝损伤中。肠道微生物群和细菌内毒素还参与了非酒精性脂肪性肝病(NAFLD)及其向非酒精性脂肪性肝炎(NASH)进展的一些机制。有实验证据表明,高脂饮食会导致NAFLD出现特征性的生态失调,拟杆菌门减少,厚壁菌门和变形菌门增加,而且肠道生态失调本身可诱发肝脂肪变性和代谢综合征。临床数据支持上述生态失调情况,但具体细节存在差异。肠道生态失调和内毒素血症在主要并发症和预后方面对肝硬化患者有很大影响。针对生态失调的宏基因组学方法可能有助于分析NASH和肝硬化中紊乱的宿主代谢。对生态失调的管理可能会成为未来肝病治疗的基石。

相似文献

1
Gut Microbiota and Host Reaction in Liver Diseases.肝脏疾病中的肠道微生物群与宿主反应
Microorganisms. 2015 Oct 28;3(4):759-91. doi: 10.3390/microorganisms3040759.
2
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.槲皮素对高脂饮食诱导的小鼠非酒精性脂肪性肝病的保护作用是通过调节肠道微生物群失衡和相关肠-肝轴激活来介导的。
Free Radic Biol Med. 2017 Jan;102:188-202. doi: 10.1016/j.freeradbiomed.2016.11.037. Epub 2016 Nov 25.
3
Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction.肠道 HIF-1α 缺失通过诱导肠道菌群失调和屏障功能障碍加重酒精性肝病。
J Hepatol. 2018 Oct;69(4):886-895. doi: 10.1016/j.jhep.2018.05.021. Epub 2018 May 25.
4
Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.口腔和肠道菌群失调与牙周炎相关非酒精性脂肪性肝病的牙周治疗和微生物组靶向治疗。
World J Gastroenterol. 2023 Feb 14;29(6):967-996. doi: 10.3748/wjg.v29.i6.967.
5
Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.具有脂肪肝和肝硬化疾病的肠道细菌的特征。
Ann Hepatol. 2019 Nov-Dec;18(6):796-803. doi: 10.1016/j.aohep.2019.06.020. Epub 2019 Sep 13.
6
Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?肠道菌群失调在肝脏疾病中的作用:我们目前了解到了什么?
Diseases. 2019 Nov 12;7(4):58. doi: 10.3390/diseases7040058.
7
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.肠道微生物群对非酒精性脂肪性肝炎发生发展的影响。
Eur J Nutr. 2018 Apr;57(3):861-876. doi: 10.1007/s00394-017-1524-x. Epub 2017 Sep 5.
8
Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.台湾经活检证实的非酒精性脂肪性肝病患者的肠道微生物失调:一项横断面研究。
Nutrients. 2020 Mar 19;12(3):820. doi: 10.3390/nu12030820.
9
Obesity, fatty liver disease and intestinal microbiota.肥胖、脂肪肝疾病与肠道微生物群
World J Gastroenterol. 2014 Nov 28;20(44):16452-63. doi: 10.3748/wjg.v20.i44.16452.
10
Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice.肠道菌群失调促进了小鼠慢性肝损伤向肝纤维化的发展。
Hepatology. 2014 May;59(5):1738-49. doi: 10.1002/hep.26695. Epub 2014 Feb 25.

引用本文的文献

1
Conjugated bile acids promote metabolic dysfunction-associated steatotic liver disease through inducing nuclear translocation of sphingosine-1-phosphate receptor 2 to disrupt peroxisome proliferator-activated receptor alpha.结合胆汁酸通过诱导鞘氨醇-1-磷酸受体2的核转位以破坏过氧化物酶体增殖物激活受体α,从而促进代谢功能障碍相关脂肪性肝病。
Cell Commun Signal. 2025 May 25;23(1):240. doi: 10.1186/s12964-025-02249-1.
2
Gut microbiota: an emerging target connecting polycystic ovarian syndrome and insulin resistance.肠道微生物群:连接多囊卵巢综合征和胰岛素抵抗的新兴靶点。
Front Cell Infect Microbiol. 2025 Mar 11;15:1508893. doi: 10.3389/fcimb.2025.1508893. eCollection 2025.
3
Liuweizhiji Gegen-Sangshen beverage protects against alcoholic liver disease in mice through the gut microbiota mediated SCFAs/GPR43/GLP-1 pathway.六味枳椇葛参饮料通过肠道微生物群介导的SCFAs/GPR43/GLP-1途径预防小鼠酒精性肝病。
Front Nutr. 2024 Dec 13;11:1495695. doi: 10.3389/fnut.2024.1495695. eCollection 2024.
4
Artificial intelligence-based evaluation of prognosis in cirrhosis.基于人工智能的肝硬化预后评估。
J Transl Med. 2024 Oct 14;22(1):933. doi: 10.1186/s12967-024-05726-2.
5
Hovenia dulcis: a Chinese medicine that plays an essential role in alcohol-associated liver disease.枳椇子:一种在酒精性肝病中发挥重要作用的中药。
Front Pharmacol. 2024 Apr 8;15:1337633. doi: 10.3389/fphar.2024.1337633. eCollection 2024.
6
Stress mechanism involved in the progression of alcoholic liver disease and the therapeutic efficacy of nanoparticles.酒精性肝病进展中涉及的应激机制和纳米粒子的治疗效果。
Front Immunol. 2023 Sep 29;14:1205821. doi: 10.3389/fimmu.2023.1205821. eCollection 2023.
7
Extract Pretreatment Alleviates Oxidative Stress and Inflammation and Increases the Abundance of Gut in Diquat-Induced Mice.提取物预处理可减轻百草枯诱导小鼠的氧化应激和炎症反应,并增加肠道菌群丰度。
Antioxidants (Basel). 2022 Sep 13;11(9):1806. doi: 10.3390/antiox11091806.
8
Microbiota-Meditated Immunity Abnormalities Facilitate Hepatitis B Virus Co-Infection in People Living With HIV: A Review.微生物群介导的免疫异常促进了 HIV 感染者合并乙型肝炎病毒感染:综述。
Front Immunol. 2022 Jan 6;12:755890. doi: 10.3389/fimmu.2021.755890. eCollection 2021.
9
Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives.肠道微生物与肝性脑病:从旧概念到新视角
Front Cell Dev Biol. 2021 Nov 26;9:748253. doi: 10.3389/fcell.2021.748253. eCollection 2021.
10
Alteration of Gut Microbiota and Its Impact on Immune Response in Patients with Chronic HBV Infection: A Review.慢性乙型肝炎病毒感染患者肠道微生物群的改变及其对免疫反应的影响:综述
Infect Drug Resist. 2021 Jul 6;14:2571-2578. doi: 10.2147/IDR.S305901. eCollection 2021.

本文引用的文献

1
Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者的小肠细菌过度生长与Toll样受体信号传导
J Gastroenterol Hepatol. 2016 Jan;31(1):213-21. doi: 10.1111/jgh.13058.
2
Hepatic TLR4 signaling in obese NAFLD.肥胖非酒精性脂肪性肝病中的肝脏Toll样受体4信号传导
Am J Physiol Gastrointest Liver Physiol. 2015 Aug 15;309(4):G270-8. doi: 10.1152/ajpgi.00304.2014. Epub 2015 Jun 25.
3
The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.非酒精性脂肪性肝病的肠道微生物群:当前方法及其解读
Hepatol Int. 2015 Jul;9(3):406-15. doi: 10.1007/s12072-015-9640-2. Epub 2015 Jun 12.
4
Alcoholic liver disease: the gut microbiome and liver cross talk.酒精性肝病:肠道微生物群与肝脏的相互作用
Alcohol Clin Exp Res. 2015 May;39(5):763-75. doi: 10.1111/acer.12704.
5
Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.肝硬化中的肠-肝轴:如何应对肠道渗漏和内毒素血症。
World J Hepatol. 2015 Mar 27;7(3):425-42. doi: 10.4254/wjh.v7.i3.425.
6
Review article: Alcohol and gut microbiota - the possible role of gut microbiota modulation in the treatment of alcoholic liver disease.综述文章:酒精与肠道微生物群——肠道微生物群调节在酒精性肝病治疗中的可能作用
Aliment Pharmacol Ther. 2015 May;41(10):917-27. doi: 10.1111/apt.13164. Epub 2015 Mar 23.
7
Recent advances in the development of farnesoid X receptor agonists.法尼醇 X 受体激动剂的研究进展。
Ann Transl Med. 2015 Jan;3(1):5. doi: 10.3978/j.issn.2305-5839.2014.12.06.
8
Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases.通过法尼醇X受体和TGR5受体的胆汁酸信号传导在肝胆和肠道疾病中的作用
Hepatobiliary Pancreat Dis Int. 2015 Feb;14(1):18-33. doi: 10.1016/s1499-3872(14)60307-6.
9
The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.法尼醇 X 受体激动剂奥贝胆酸可预防胆汁淤积大鼠肠道屏障功能障碍和细菌易位。
Am J Pathol. 2015 Feb;185(2):409-19. doi: 10.1016/j.ajpath.2014.10.009. Epub 2015 Jan 12.
10
The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease.肠道细菌过度生长在肥胖相关非酒精性脂肪性肝病中的作用。
Nutrients. 2014 Dec 3;6(12):5583-99. doi: 10.3390/nu6125583.